Kaposi's sarcoma ± associated herpesvirus / human herpesvirus 8 ( KSHV / HHV8 ) has been etiologically associated with several malignancies including Kaposi's sarcoma and primary effusion lymphoma. Oncogenic viral interferon regulatory factor ( vIRF ) encoded by KSHV ORF -K9 is a homologue of cellular interferon regulatory factor ( IRF ) , and has been demonstrated to inhibit type I / II interferon signal transduction and transform NIH3T3 cells through the interactions with IRF -1, IRF -3, and CBP / p300 proteins. To counteract vIRF's pathogenic role, we have developed five ribozymes targeting ORF -K9 mRNA to suppress vIRF expression. The vIRF RNA substrates were cleaved up to 80% in a substrate -specific manner in transcript cleavage assays in vitro. In a transient transfection assay, two of the ribozymes efficiently suppressed the expression of vIRF protein measured by dual -color immunofluorescence assay that simultaneously detects the expression of both vIRF protein and ribozyme. Flow cytometry analysis showed that these ribozymes reduced vIRF expression up to 76%. A mutant ribozyme had no cleavage activity in vitro, but exhibited antisense effect in vivo. These results suggest that the ribozymes may provide a new approach for functional knockout of vIRF gene, and are potential candidates of antiviral therapy for KSHV -related malignancies. Cancer Gene Therapy ( 2001 ) 8, 285 ± 293
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KSHV ORF -K9 encodes a viral interferon regulatory factor ( vIRF ), which has homology to members of the cellular interferon regulatory factor (IRF) family. The vIRF interacts with IRF-1, IRF-3, and CBP /P300 proteins to inhibit type I /II human interferon (IFN ) signaling and cause transformation of NIH3T3 cells. 2 ± 6 The IRF family members are transcription regulatory factors that bind to interferonstimulated response elements to regulate interferon-responsive genes involved in pathogenic response, cytokine signaling, cell growth regulation, and hematopoietic development. 7 The vIRF protein directly interacts with these DNA -binding proteins to interfere with their functions. For example, vIRF down -regulates MYC proto -oncogene and cyclin-dependent protein kinase inhibitor p21 WAF1 / CIP1 , 2, 6 both of which are interferon -responsive genes involved in cell cycle checkpoint and progression. 8 ± 11 Furthermore, we have detected vIRF protein expression in PEL cell lines and KS lesions using a vIRF -specific monoclonal antibody ( unpublished data ). These data suggest that vIRF is a genuine oncogene and may play important roles in the development of KSHV-associated malignancies. Thus, vIRF gene is a potential target for antiviral gene therapy of KSHVassociated malignancies.
We have selected ribozyme approach to inactivate vIRF gene through cleavage of its mRNA because ribozyme is highly specific and lacks immunogenicity. Ribozymes, also known as catalytic RNA or RNA enzymes, are capable of specifically cleaving deleterious RNA or repairing mutant cellular RNAs. 12 They form base pair ± specific complexes with their substrates and catalyze the hydrolysis of specific phosphodiester bonds, causing RNA strand cleavage. Ribozymes have been used for antiviral therapy by cleavage of viral genes, 13, 14 treatments of cancer and genetic disorders, 15 ± 18 functional study of genes, and elucidation of signaling pathways and target validation. 19, 20 The most extensively used ribozymes are hairpin and hammerhead ribozymes. The hammerhead ribozyme initially derived from plant viroids 21 is betterstudied and has fewer stringent requirements on target sequence than hairpin ribozyme. Because hammerhead ribozyme is smaller than the hairpin ribozyme, it is less expensive to synthesize and easier to obtain higher yields.
The purpose of the present study was to develop hammerhead ribozymes targeting KSHV K9 gene and determine their cleavage efficiency in vitro using a cell-free assay and in vivo in a transient transfection assay. Several functional ribozymes that are capable of cleaving vIRF transcripts in vitro and suppressing vIRF expression in vivo have been successfully developed.
MATERIALS AND METHODS

Cell line
HeLa Tet -Off cell line was obtained from Clontech ( Palo Alto, CA ) and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum.
Selection of ribozyme target sites
The optimal K9 mRNA target sites were chosen for hammerhead ribozymes using MFOLD program ( Genetics Computer Group, version 8.1, Madison, WI ) , which predicts the optimal and suboptimal RNA secondary structures based on free energy minimization method. 22 The linear structure of the mRNA was converted into a two -dimensional stemloop format. The structure containing the least energy change of formation was used for further consideration. The potential cleavage sites are NUH triplets (H =A, C, or U ) within the single -stranded, looped regions of the twodimensional structure with the surrounding 20 -nucleotide ( nt ) sequences sharing no homology to other non -K9 mRNA targets.
Construction and synthesis of hammerhead ribozymes
Ribozyme DNA fragments were prepared by synthesis of two oligodeoxynucleotides ( Table 1 ) with 15 nt complementary to each other followed by extension with DNA polymerase. To synthesize the ribozymes by in vitro transcription, the DNA fragments were either used directly or cloned into the vector pcDNA3.0 (Invitrogen, San Diego, CA ) .
For transfection into HeLa Tet -Off cells, the ribozyme DNA fragments were subcloned into pBI -EGFP vector ( Clontech ), which contains two bi -directional identical minimal CMV promoters that can drive the expression of both the cloned ribozyme and green fluorescent protein ( GFP ) in HeLa Tet -Off cell line.
Preparation of truncated substrate transcripts
The truncated transcripts corresponding to 1 ±135, 1± 536, and 1135 ±1336 bp of ORF -K9 were used as substrates to determine the ribozyme cleavage efficiency in vitro. The DNA fragments were polymerase chain reaction ( PCR ) ± amplified from KSHV-infected BC -1 cells 23 and cloned into PCRII cloning plasmid (Invitrogen ) . The radiolabeled RNA substrates were synthesized by T7 RNA polymerasedirected in vitro transcription of BamHI -linearized PCRII plasmid constructs in the presence of [ -32 P ] CTP following manufacturer's instructions (Promega, Madison, WI ) .
Substrate cleavage in vitro by ribozyme
The hammerhead ribozyme transcripts were synthesized by in vitro transcription with T7 RNA polymerase. The cleavage reactions were carried out as previously described with minor modifications. 24 Briefly, the radiolabeled RNA substrate and the ribozyme ( s) were mixed at a molar ratio 1:5. The cleavage reaction was initiated by addition of 10 mM MgCl 2 to the mixtures followed by incubation at 378C. The cleavage products were resolved electrophoretically on a 5% polyacrylamide gel containing 7 M urea, visualized with a GS -525 Molecular Imager System (Bio -Rad Laboratories, Richmond, CA ) , and quantified with a Multi -Analyst program (Bio -Rad ) . To monitor the kinetics of the enzymatic cleavage, the cleavage mixtures were removed in aliquots at different time points and assayed for their cleavage products.
Immunofluorescence assay ( IFA ) and flow cytometry analysis
An expression construct containing the full -length ORF -K9 2 was subcloned into pCMV-Tag2 vector (Stratagene, La Jolla, CA ). The resulting plasmid named pCMV-K9 was used to assess the ribozyme cleavage efficiency in vivo. The HeLa cells were co -transfected with pCMV-K9 and ribozyme constructs using LipofectAmine 2000 ( Life Technologies, Rockville, MD ) according to manufacturer's instructions. After 24 -hour incubation at 378C, the cells were fixed with 4% paraformaldehyde, and then permeabilized with 0.2% saponin at room temperature for 30 minutes, respectively. vIRF protein expression was detected with a 
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monoclonal antibody 2H5 specific for vIRF protein (Gao et al, manuscript in preparation ) and a goat antimouse IgG conjugated with rhodamine. The stained cells were observed with a fluorescent microscope. For flow cytometry analysis, the HeLa cells were trypsinized before fixation and permeation as described above. The vIRF monoclonal antibody 2H5 and a goat antimouse IgG R ± phycoerythrin ( PE ) conjugate were used to detect vIRF protein expression. The stained cells were resuspended in phosphate -buffered saline, pH 7.4, and analyzed on an Epics Elite Flow Cytometer (BeckmanCoulter, Miami, FL ) following manufacturer's instructions. Cells exhibiting fluorescein isothiocynate fluorescence were detected with a 525 -nm bandpass filter, whereas cells exhibiting phycoerythrin fluorescence were detected with a 575 -nm bandpass filter. A total of 50,000 cells were collected from the main population of cells. Unstained and stained nontransfected cells were used as negative controls. Percentages of GFP -positive cells in all treatments were compared with that transfected with vector control to calibrate the transfection efficiency. Percentages of dual -color cells and vIRF -expressing cells were then compared with that of vector control to determine the suppression efficiency of ribozymes.
RESULTS
Selection of cleavage sites and design of the vIRF -specific hammerhead ribozymes
To achieve the highest accessibility of ribozymes to the KSHV ORF -K9 mRNA, we examined its potential secondary structure through the energy minimization approach. The potential stem -loop configuration of the K9 mRNA was built from the entire encoding region of ORF -K9 (Fig 1A ) . Looped regions with NUH triplets and at least 50% A + U contents were selected and examined for minimal homology with any cellular sequence by Blast search in GenBank. Five potential cleavage sites for ribozyme cleavage were identified at position +66, + 420, + 1190, +1228, and +1254, and selected for ribozyme design. As the arm length of hammerhead ribozyme affects its optimum substrate specificity and turnover rate, 12 we selected two different arm lengths for ribozymes. The ribozymes with two side arms of 19 ± 21 residues each were selected for cleavage sites + 66, + 1190, and + 1254, and designated as R1, R2, and R3, respectively. The ribozymes with two side arms of 9 ±11 residues each were selected for cleavage sites +420, and + 1228, and designated as RZ1 and RZ2, respectively. The sequence structures of these ribozymes are shown in Figure 1B ±F, respectively.
It has been established that the substitution of two bases at the catalytic core of the hammerhead ribozyme (A!C, and G!U, as indicated in Figure 1B ) causes an almost total loss of the catalytic activity without any significant change in base pairing capacity of the ribozyme. 24 Therefore, we designed a RZ1 mutant ribozyme, RZ1M, to assess the specificity and the antisense effects of the ribozyme.
Catalytic cleavage of K9 mRNA substrates in vitro
The specificity and catalytic activities of the ribozymes were examined using 32 P-labeled RNA substrates. The target substrate used for R1 was a 184-nt ± long RNA synthesized in vitro. A 336 -nt ±long RNA was used as substrate for R2, R3, and RZ2, and a 652 -nt ± long RNA was used for RZ1. Electrophoretic gel images of cleavage reactions showed that all the ribozymes cleaved their substrates, yielding excision products as expected ( Fig 2) . R1 cleavage yielded two expected products of 148 and 36 nt in size (Fig 2A ) . R2 cleavage yielded two expected bands of 189 and 147 nt in size. R3 cleavage yielded two expected bands of 211 and 125 nt in size. The ribozymes R1, R2, and R3 cleaved their target substrates by 21%, 40%, and 36%, respectively, within 2 hours (Fig 2A ) . The incubation of R1 with the substrate of R2, and R2 with the substrate of R1 did not yield any excision products ( Fig 2A ) , indicating the specificity of the ribozyme cleavage. The ribozyme RZ1 efficiently cleaved its substrate, whereas the mutant ribozyme RZ1M had no cleavage activity as expected ( Fig 2B ) . Similar to R1, R2, and R3, RZ1 cleaved its 652-nt RNA substrate in a highly sequence -specific manner and produced two products of the expected sizes, 494 and 158 nt (Fig 2B ) . Time course experiment showed that RZ1 cleaved 61% of its substrate within 60 minutes and 75% within 120 minutes (Fig 2, C  and D ) . In contrast, extended incubation of the mutant ribozyme, RZ1M, with the same substrate did not yield any excision product, indicating the absence of endonuclease activity of the ribozyme. RZ2 cleaved its target substrate by 15% within 60 minutes and yielded two expected products ( data not shown ). Collectively, these results demonstrated the catalytic activity and substrate specificity of RZ1 ribozyme.
Effects of ribozymes on the vIRF protein expression in transiently transfected cells
We further determined the ribozyme activities in transiently transfected HeLa cells. Dual -color IFA was performed to simultaneously examine the expression of ribozyme and vIRF gene in the transfected cells. The presence of GFP in HeLa cells was indicative of ribozyme expression as the ribozyme and GFP were cloned into a bi -directional expression vector under the control of the same tetracycline-responsive element. The vIRF protein expressed in HeLa cells was stained to red color to differentiate from GFP fluorescence. If the ribozymes have high cleavage efficiency in vivo, it was anticipated that the number of dual -color fluorescent cells would be reduced. Because of the relative low efficiency of transient transfection ( 10± 30% ), some cells will only express the ribozyme but not the vIRF protein. Thus, the number of red cells was also expected to be reduced, but to a less extent. For this reason, the number of dual -color fluorescent cells is a better indicator than the number of vIRF-positive cells for measuring the suppression effect of the ribozymes. Compared with mutant ribozyme RZ1M, ribozyme RZ1 significantly reduced the number of dual -color cells and the number of cells expressing vIRF protein (red color ) ( Fig 3 ) , indicating the efficient suppression of vIRF protein expression. Other ribozymes R1, R2, R3, and RZ2 also suppressed the vIRF expression by reducing the number of dual -color cells and the number of cells expressing vIRF protein to various degrees compared with those of vector control ( data not shown ).
Flow cytometry analysis was used to examine the effects of ribozyme on vIRF expression in co -transfected HeLa cells by monitoring the cell population change of dual -color, green, or red cells. Compared with vector control, R1, R2, R3, RZ1, and RZ2 reduced dual -color cells by 76%, 43%, 44%, 59%, and 42% (Fig 4) , respectively, which demonstrated the suppression effect of the ribozymes. The mutant ribozyme RZ1M also reduced dual -color cells by 39%, indicating that it had antisense effect. As expected, ribozymes R1, R2, R3, RZ1, RZ2, and RZ1M also reduced the cells expressing vIRF protein alone, but to a less extent, by 72%, 34%, 35%, 46%, 35%, and 14%, respectively, compared with that of vector control (Fig 4 ) . These results indicated that R1 had the highest cleavage efficiency, followed by RZ1 and the others.
DISCUSSION
Ribozymes have been applied to overcome malignancies by suppressing the function of the oncogenes 25 ± 27 and inhibit HIV-1 replication by targeting viral genes.
14,28 Ribozyme targeting scatter factor /hepatocyte growth factor and c-met expression has successfully reduced cell clonogenicity and inhibited tumor growth of human glioblastoma malignancy. 26 Adenovirus -mediated anti ± H -ras ribozyme has caused complete regression of the tumor in an experimental gene therapy of human bladder cancer. 29 Ribozymemediated suppression of aberrant epidermal growth factor receptor gene has been reported to inhibit the growth of tumors formed by cells expressing the aberrant gene. 30 These studies demonstrate the potential application of ribozyme in cancer gene therapy. In the development of KSHV-induced malignancies, the oncogenic vIRF may have important roles because it is capable of causing cellular transformation and inhibiting IFN signal transduction through interaction with IRF -1, IRF -3, and CBP /p300 proteins.
2,3,6,31 Development of ribozymes targeting IRF gene may provide a potential approach of antiviral gene therapy for KSHV-associated malignancies, and a new tool for further studies of vIRF's functions.
In the present study, ribozymes were developed against oncogene vIRF and evaluated in both in vitro and in vivo testing systems. The cleavage sites were selected based on energy minimization approach, which may not reflect the true secondary structure of K9 in vivo, but provides the first step to identify the potential target sites. Various factors contribute to the cleavage efficiency of ribozyme both in vitro and in vivo. The arm length of ribozyme was thought to affect the turnaround rate and stability of ribozyme, and the duplex formation in vivo. The accessibility of the target site on the substrate by the ribozyme also affects its cleavage efficiency. We designed and tested five ribozymes targeting different K9 mRNA sites with two different arm lengths, one short and one long in the N -terminal, and one short and two long in the C -terminal of vIRF gene. It appears that the two ribozymes targeting the N -terminal sites ( +66 and +420 ) worked better than those targeting the C -terminal sites ( + 1190, + 1228, and +1254) . In vitro, the ribozyme RZ1 with short arm -length exhibited higher efficiency of substrate cleavage than other ribozymes possibly because of its quick turnaround rate. Ribozyme RZ1 cleaved 75% of its substrate in vitro in 2 hours, whereas the mutant ribozyme did not have any cleavage activity, indicating the specific cleavage activity of RZ1. The other ribozymes cleaved up to 40% substrate in vitro. It has been suggested that the secondary structure of ribozyme is important in determining its function. Among these ribozymes, RZ1 exhibited the most ideal noncomplementary arms in secondary structure, ensuring excess free molecules for binding to its target RNA. In vivo, the long arm -length ribozyme R1 exhibited the best efficiency though it had limited function in vitro. It is possible that the R1 target site is more accessible in vivo than in vitro. However, longer arm -length could also increase the stability of the ribozyme as well as the probability of forming duplex, and thus increase the specificity of the ribozymes. ZHANG, WANG, DENG, ET AL: RIBOZYME-MEDIATED SUPPRESSION OF KSHV-ENCODED vIRF IFA and flow cytometry analysis have demonstrated that these ribozymes had specific cleavage function in vivo. Cloning the ribozyme DNA into GFP reporter vector provides a tool to monitor the expression of ribozyme because both GFP and ribozyme were under the control of two identical promoters driven by the same tetracycline response element. Thus, GFP and ribozyme are expected to express at a similar level. Because vIRF protein expression could be detected by vIRF -specific monoclonal antibody, dual -color fluorescence assay was used to monitor the expression level of both ribozyme and vIRF protein in the same cell. The reduction of dual -color cells and cells expressing vIRF protein is an indication of suppression of vIRF protein expression. Compared with vector control, these ribozymes reduced dual -color cells and vIRF protein ± positive cells, suggesting that they had cleavage function in vivo. Compared with mutant ribozyme, RZ1 had fewer dual -color cells and vIRF protein ± positive cells, further confirming its in vivo cleavage effect.
Flow cytometry analysis provides quantitative determination of the ribozyme cleavage. Ribozymes R1 and RZ1 had higher cleavage efficiency than others as they reduced more significantly the number of dual -color cells and vIRF protein ± positive cells. Compared with vector control, RZ1M, mutant ribozyme for RZ1, also reduced the number of dual -color cells and vIRF -positive cells, suggesting its antisense effect in vivo. All the ribozymes and RZ1M reduced more cells with dual colors than cells expressing vIRF protein alone. This is likely due to the relative low efficiency of transient transfection, in which only a portion of cells could be simultaneously transfected with both ribozyme and vIRF constructs. This could also be one of the reasons that both R1 and RZ1 ribozymes did not reduce vIRF -positive cells to zero. Furthermore, the turnaround rate of the ribozymes and short half -life could contribute to the suppression rates of vIRF protein expression. If the half -life of ribozyme RNA were shorter than that of the GFP protein which was used as an indicator of ribozyme expression, then the ribozyme expression rate could be overestimated. The development of these ribozymes may provide a new approach for functional knockout of individual viral genes, and the ribozymes are potential candidates of antiviral gene therapy for KSHVassociated malignancies.
